394 related articles for article (PubMed ID: 33781507)
1. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Estevez-Ordonez D; Chagoya G; Salehani A; Atchley TJ; Laskay NMB; Parr MS; Elsayed GA; Mahavadi AK; Rahm SP; Friedman GK; Markert JM
Neurosurg Clin N Am; 2021 Apr; 32(2):265-281. PubMed ID: 33781507
[TBL] [Abstract][Full Text] [Related]
2. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
3. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Saha D; Martuza RL; Rabkin SD
Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.
Kazemi Shariat Panahi H; Dehhaghi M; Lam SS; Peng W; Aghbashlo M; Tabatabaei M; Guillemin GJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1122-1142. PubMed ID: 34004331
[TBL] [Abstract][Full Text] [Related]
6. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
[TBL] [Abstract][Full Text] [Related]
7. Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK
Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285
[TBL] [Abstract][Full Text] [Related]
8. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
Kardani K; Sanchez Gil J; Rabkin SD
Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
[TBL] [Abstract][Full Text] [Related]
10. Promises of oncolytic viral therapy for adult and children with brain glioma.
Patiño-García A; Alonso MM; Gállego Pérez-Larraya J
Curr Opin Oncol; 2023 Nov; 35(6):529-535. PubMed ID: 37820087
[TBL] [Abstract][Full Text] [Related]
11. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Czarnywojtek A; Borowska M; Dyrka K; Van Gool S; Sawicka-Gutaj N; Moskal J; Kościński J; Graczyk P; Hałas T; Lewandowska AM; Czepczyński R; Ruchała M
Pharmacology; 2023; 108(5):423-431. PubMed ID: 37459849
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM; Friedman GK; Cassady KA; Markert JM
Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902
[TBL] [Abstract][Full Text] [Related]
16. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
Kanai R; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
[TBL] [Abstract][Full Text] [Related]
17. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
19. Design and application of oncolytic HSV vectors for glioblastoma therapy.
Grandi P; Peruzzi P; Reinhart B; Cohen JB; Chiocca EA; Glorioso JC
Expert Rev Neurother; 2009 Apr; 9(4):505-17. PubMed ID: 19344302
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L; Wakimoto H
Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]